Lunit to Present 3 AI Biomarker Studies at World Conference on Lung Cancer
TECHWORLD ·
✦ AI Summary
Lunit plans to present three research abstracts using Lunit Scope IO at the 2026 World Conference on Lung Cancer (WCLC 2026), which runs from the 12th to the 15th.
The first study analyzed differences in the tumor microenvironment by EGFR mutation subtype; Ex19del had a high density of tumor-infiltrating lymphocytes, L858R showed prominent macrophage infiltration, and Ex20ins had the highest density of vascular endothelial cells.
The second study examined the relationship between pCR and the tumor microenvironment in 32 NSCLC patients who received preoperative chemoimmunotherapy, and the final study analyzed the relationship between TP53 mutation status and immune activation and immune-excluded patterns in 462 patients with lung adenocarcinoma.
Lunit plans to present three research abstracts using its AI biomarker platform, Lunit Scope IO, at the 2026 World Conference on Lung Cancer (WCLC 2026), which runs from the 12th to the 15th. The disclosed findings are analyses of the links between AI-based lung cancer genetic mutations, the tumor microenvironment, and treatment response.
The first study introduced this time analyzed differences in the tumor microenvironment by EGFR mutation subtype in non-small cell lung cancer (NSCLC), targeting EGFR-mutated subtypes. The study used 494 whole-slide images with confirmed EGFR mutation subtypes, and Lunit Scope IO was applied in the analysis.
The analysis found that Ex19del had a high density of tumor-infiltrating lymphocytes, while L858R showed prominent macrophage infiltration. Ex20ins, meanwhile, showed the highest density of vascular endothelial cells.
The findings confirmed that even within EGFR-mutated lung cancer, there are differences in the tumor microenvironment depending on subtype. The study also suggested that these differences could be used in future analyses of subtype-specific treatment response and in developing treatment strategies.
The second study focused on treatment response in patients with non-small cell lung cancer who received preoperative chemoimmunotherapy. Lunit jointly analyzed tissue from 32 patients with a research team led by Dr. Paola Nistico at the National Cancer Institute Regina Elena in Italy, aiming to identify the relationship between pathological complete response (pCR) and the tumor microenvironment. The analysis found that patients who achieved pCR had active immune-cell infiltration, and tertiary lymphoid structures (TLS), which regulate immune responses, were also prominent.
By contrast, patients who did not achieve pCR showed an immune-excluded pattern, with insufficient immune-cell infiltration into the tumor. Tumor-cell proliferation was also observed in these cases. The research team said such differences could be used to develop biomarkers for determining the need for postoperative adjuvant therapy in the future.
In the final study, the relationship between TP53 mutations and the tumor microenvironment was analyzed using tissue from 462 patients with lung adenocarcinoma. The results showed that cancers with TP53 mutations had a higher proportion of immune activation, while cases without TP53 mutations showed an immune-excluded pattern. In addition, cases without TP53 mutations had higher stromal fibroblast density and higher endothelial cell density.
Lunit confirmed the possibility of predicting whether TP53 mutations are present based on tumor microenvironment features in tissue images. Accordingly, the AI biomarker could be used for pregenetic-testing patient selection and for establishing treatment strategies by mutation status.
Lunit CEO Seo Beom-seok said the company had identified clues at the World Conference on Lung Cancer linking genetic mutations, the tumor microenvironment, and treatment response with AI. He added that the company aims to contribute to suggesting precision treatment strategies for cancer patients through the use of Lunit Scope.
Source: TECHWORLD · Kim Seung-gi
Original: https://www.epnc.co.kr/news/articleView.html?idxno=406701
References
This article was produced with the help of an automated content generation algorithm.
Source: TECHWORLD
View originalThis article was summarized and organized by BizCrush based on the original article from TECHWORLD. For exact quotations and full details, please refer to the original article.